Terms: = Lymphoma AND NOTCH2, Q04721, 4853, ENSG00000134250, AGS2, hN2 AND Treatment
52 results:
1. Pathogenic Variants Associated with Epigenetic Control and the NOTCH Pathway Are Frequent in Classic Hodgkin lymphoma.
Santisteban-Espejo A; Bernal-Florindo I; Montero-Pavon P; Perez-Requena J; Atienza-Cuevas L; Fernandez-Valle MDC; Villalba-Fernandez A; Garcia-Rojo M
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473705
[TBL] [Abstract] [Full Text] [Related]
2. Relapsed/Refractory Peripheral T-Cell lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline Mutations.
Yang T; Chen R; Zhang M; Jing R; Geng J; Wei G; Luo Y; Xiao P; Hong R; Feng J; Fu S; Zhao H; Cui J; Huang S; Huang H; Hu Y
Cell Transplant; 2024; 33():9636897231221887. PubMed ID: 38183241
[TBL] [Abstract] [Full Text] [Related]
3. Primary central nervous system marginal zone lymphoma.
Flospergher E; Marino F; Calimeri T; Cangi MG; Ferreri AJM; Ponzoni M; Bongiovanni L
Br J Haematol; 2024 Jan; 204(1):31-44. PubMed ID: 38054330
[TBL] [Abstract] [Full Text] [Related]
4. NOTCH Signaling in Mantle Cell lymphoma: Biological and Clinical Implications.
Deshotels L; Safa FM; Saba NS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373427
[TBL] [Abstract] [Full Text] [Related]
5. Mechanism of action of chlormethine gel in mycosis fungoides.
Guenova E; Ortiz-Romero PL; Poligone B; Querfeld C
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1739-1748. PubMed ID: 37262305
[TBL] [Abstract] [Full Text] [Related]
6. DLBCL-associated notch2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
Zhou N; Choi J; Grothusen G; Kim BJ; Ren D; Cao Z; Liu Y; Li Q; Inamdar A; Beer T; Tang HY; Perkey E; Maillard I; Bonasio R; Shi J; Ruella M; Wan L; Busino L
Blood; 2023 Sep; 142(11):973-988. PubMed ID: 37235754
[TBL] [Abstract] [Full Text] [Related]
7. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.
Tatarczuch M; Waltham M; Shortt J; Polekhina G; Hawkes EA; Ho SJ; Trotman J; Brasacchio D; Co M; Li J; Ramakrishnan V; Dunne K; Opat SS; Gregory GP
Blood Adv; 2023 Jul; 7(14):3531-3539. PubMed ID: 36947202
[TBL] [Abstract] [Full Text] [Related]
8. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
[TBL] [Abstract] [Full Text] [Related]
9. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
Dlouhy I; Karube K; Enjuanes A; Salaverria I; Nadeu F; Ramis-Zaldivar JE; Valero JG; Rivas-Delgado A; Magnano L; Martin-García D; Pérez-Galán P; Clot G; Rovira J; Jares P; Balagué O; Giné E; Mozas P; Briones J; Sancho JM; Salar A; Mercadal S; Alcoceba M; Valera A; Campo E; López-Guillermo A
Br J Haematol; 2022 Feb; 196(3):589-598. PubMed ID: 34632572
[TBL] [Abstract] [Full Text] [Related]
10. Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.
Vela V; Juskevicius D; Dirnhofer S; Menter T; Tzankov A
Virchows Arch; 2022 Feb; 480(2):403-413. PubMed ID: 34494161
[TBL] [Abstract] [Full Text] [Related]
11. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract] [Full Text] [Related]
12. Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.
Mishina T; Oshima-Hasegawa N; Tsukamoto S; Fukuyo M; Kageyama H; Muto T; Mimura N; Rahmutulla B; Nagai Y; Kayamori K; Hino Y; Mitsukawa S; Takeda Y; Ohwada C; Takeuchi M; Tsujimura H; Iseki T; Nakaseko C; Ikeda JI; Itami M; Yokote K; Ohara O; Kaneda A; Sakaida E
Br J Haematol; 2021 Dec; 195(5):731-742. PubMed ID: 34378195
[TBL] [Abstract] [Full Text] [Related]
13. The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border.
Grant AH; Ayala-Marin YM; Mohl JE; Robles-Escajeda E; Rodriguez G; Dutil J; Kirken RA
Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299796
[TBL] [Abstract] [Full Text] [Related]
14. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.
Ishiguro K; Sasaki Y; Takagi Y; Niinuma T; Suzuki H; Tokino T; Hayashi T; Takahashi T; Igarashi T; Matsuno Y
Medicine (Baltimore); 2020 Aug; 99(35):e21938. PubMed ID: 32871937
[TBL] [Abstract] [Full Text] [Related]
15. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
[TBL] [Abstract] [Full Text] [Related]
17. Genomic Alterations and MYD88
Jiang S; Qin Y; Gui L; Liu P; Jiang H; Liu B; Yang J; Yang S; He X; Zhou S; Du X; Yi Y; Lin J; Shi Y
Target Oncol; 2020 Apr; 15(2):221-230. PubMed ID: 32239385
[TBL] [Abstract] [Full Text] [Related]
18. Systematic literature review of the global burden of illness of mantle cell lymphoma.
Monga N; Garside J; Quigley J; Hudson M; O'Donovan P; O'Rourke J; Tapprich C; Parisi L; Davids MS; Tam C
Curr Med Res Opin; 2020 May; 36(5):843-852. PubMed ID: 32162977
[No Abstract] [Full Text] [Related]
19. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
[TBL] [Abstract] [Full Text] [Related]
20. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.
Jain P; Wang M
Am J Hematol; 2019 Jun; 94(6):710-725. PubMed ID: 30963600
[TBL] [Abstract] [Full Text] [Related]
[Next]
